GlassScriptPhysician profile
Latchman Hardowar
NPI 1043279151
$657.86
in general payments reported to CMS, 2019-2025
15 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.14 · 2021: $35.79 · 2023: $213 · 2024: $244 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $158.22 | 2021-2024 | |
| Pfizer INC. | $110.82 | 2021-2025 | |
| Alkermes, INC. | $72.81 | 2023 | Lybalvi |
| Amgen INC. | $56.49 | 2024 | Repatha, Otezla |
| Novo Nordisk INC | $48.84 | 2023 | Rybelsus, Ozempic |
| Ucb, INC. | $33.25 | 2019 | |
| Boston Scientific Corporation | $31.87 | 2025 | Watchman Flx |
| Csl Behring | $23.31 | 2025 | Andembry |
| Phathom Pharmaceuticals, INC. | $22.58 | 2024 | Voquezna |
| Lilly USA, LLC | $20.79 | 2024 | Mounjaro |
| Lundbeck LLC | $18.56 | 2024 | Rexulti |
| Shield Therapeutics INC | $17.35 | 2023 | Accrufer |
| Exact Sciences Corporation | $16.18 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.90 | 2025 | Caplyta |
| Kvk-Tech, INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latchman Hardowar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.